Triple-negative breast cancer (TNBC) is an aggressive tumor with few effective treatment options characterized by the absence of estrogen receptor, progesterone receptor and HER2 (human epidermal growth factor receptor-2) expression but high levels of XBP1s expression. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.